47P Real-world outcomes of immune checkpoint inhibitors and selective RET inhibitors for RET fusion non-small cell lung cancer

Abstract

Selective RET inhibitors has been approved for RET fusion non-small cell lung cancer (NSCLC) after failure of platinum-based chemotherapy. However, whether RET fusion NSCLC could benefit from immune checkpoint inhibitors (ICIs) remain unclear. This study retrospectively analyzed clinical outcomes of ICIs and RET inhibitors in RET fusion advanced NSCLC.